Macrogenics (MGNX) Other Working Capital Changes (2012 - 2026)
Macrogenics (MGNX) reported Other Working Capital Changes of -$252000.0 for Q1 2026, up 92.87% year-over-year from -$130657.1 in Q1 2025, and down 104.44% quarter-over-quarter from $5.7 million in Q4 2025.
Macrogenics (MGNX) Other Working Capital Changes (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has 15 years of Other Working Capital Changes data on file, last reported at -$252000.0 in Q1 2026.
- Other Working Capital Changes for Q1 2026 came in at -$252000.0, up 92.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.3 million (up 125.5% YoY), and the FY2024 annual result was -$9.4 million, down 4278.6% from the prior year.
- Other Working Capital Changes fell to -$252000.0 in Q1 2026 per MGNX's latest filing, from $5.7 million in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $14.0 million in Q4 2022 and troughed at -$19.9 million in Q2 2022.
- A 5-year average of $244941.2 and a median of -$75000.0 in 2024 frame the typical range for Other Working Capital Changes.
- On a YoY basis, Other Working Capital Changes climbed as much as 810.41% in 2022 and fell as far as 7406.04% in 2022.
- A 5-year view of Other Working Capital Changes shows it stood at $14.0 million in 2022, then tumbled by 96.38% to $508000.0 in 2023, then sank by 1978.35% to -$9.5 million in 2024, then surged by 159.53% to $5.7 million in 2025, then slumped by 104.44% to -$252000.0 in 2026.
- Business Quant data shows MGNX's Other Working Capital Changes at -$252000.0 in Q1 2026, $5.7 million in Q4 2025, and -$5.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Macrogenics | 260.14 Mn | 193.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -252,000.00 |
| Mar 31, 2026 | -252,000.00 |
| Dec 31, 2025 | 5.68 Mn |
| Dec 31, 2025 | 5.68 Mn |
| Sep 30, 2025 | -5.52 Mn |
| Sep 30, 2025 | -5.52 Mn |
| Jun 30, 2025 | 3.38 Mn |
| Jun 30, 2025 | 3.38 Mn |
| Mar 31, 2025 | -3.54 Mn |
| Mar 31, 2025 | -3.54 Mn |
| Dec 31, 2024 | -9.54 Mn |
| Dec 31, 2024 | -9.54 Mn |
| Sep 30, 2024 | 1.70 Mn |
| Sep 30, 2024 | 1.70 Mn |
| Jun 30, 2024 | -1.50 Mn |
| Jun 30, 2024 | -1.50 Mn |
| Mar 31, 2024 | -75,000.00 |
| Mar 31, 2024 | -75,000.00 |
| Dec 31, 2023 | 508,000.00 |
| Dec 31, 2023 | 508,000.00 |